New pharmacologic therapies in gastrointestinal disease

Gastroenterol Clin North Am. 2010 Sep;39(3):709-20. doi: 10.1016/j.gtc.2010.08.020.

Abstract

Many gastrointestinal diseases remain poorly responsive to therapies, and even in the cases of conditions for which there are many effective drugs, there is still considerable room for improvement. This article is focused on drugs for digestive disorders that have entered the marketplace recently, or are expected to reach the marketplace within the next 1 to 2 years. Although advances have been made in understanding gastrointestinal motility, visceral pain, mucosal inflammation, and tissue repair, the major gastrointestinal diseases remain as significant therapeutic challenges.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Constipation / drug therapy
  • Enzyme Inhibitors / therapeutic use
  • Gastric Acid / metabolism*
  • Gastrointestinal Agents / therapeutic use*
  • Gastrointestinal Diseases / drug therapy*
  • Gastrointestinal Diseases / physiopathology
  • Gastrointestinal Motility / drug effects*
  • Histamine H2 Antagonists / therapeutic use
  • Humans
  • Potassium / metabolism
  • Proton Pump Inhibitors / therapeutic use
  • Serotonin Receptor Agonists / therapeutic use
  • Short Bowel Syndrome / drug therapy

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Enzyme Inhibitors
  • Gastrointestinal Agents
  • Histamine H2 Antagonists
  • Proton Pump Inhibitors
  • Serotonin Receptor Agonists
  • Potassium